News Presentations Publications

FILTERS

TOPICS

CritiTech PES partner NanOlogy Named to BioSpace Top 20 Life Science Startups to Watch in 2019

BioSpace is proud to present its NextGen Bio “Class of 2019,” a list of 20 up-and-coming life science companies in North America that launched* … Continued

More >

Wuxi AppTec: Small Molecule Chemotherapy May Play a Big Role in Cancer Immunotherapy

The combination of chemotherapies and immunotherapies highlights the significance of small molecule drug development as an ongoing treatment modality. Although … Continued

More >

CritiTech Particle Engineering Solutions Presents at BARDA Industry Day 2019

FOR IMMEDIATE RELEASEOctober 24, 2018 CritiTech Particle Engineering Solutions Presents at BARDA Industry Day 2019 CritiTech Particle Engineering Solutions was … Continued

More >

CritiTech Particle Engineering Solutions Launches New Pharmaceutical Spray Drying Business

FOR IMMEDIATE RELEASEMay 30, 2018 LAWRENCE, KS – CritiTech Particle Engineering Solutions, a growing Contract Development Manufacturing Organization (CDMO) and … Continued

More >

NanOlogy to Unveil Positive Preclinical Data for Inhaled NanoPac® in Treatment of Lung Cancer at 2018 ASCO Annual Meeting

Update – 6/4/18:  Link to NanOlogy Poster presented at 2018 ASCO Annual Meeting Studies of Inhaled NanoPac Show Prolonged Retention … Continued

More >

New Cancer Answer

FORT WORTH, Texas—Researchers have been trying to develop therapeutic agents powerful enough to destroy tumors without harmful effects to healthy … Continued

More >

NanOlogy Takes Nanoparticle Tech into Phase II Trials

OCTOBER 16, 2017 BY SARAH FAULKNER In the last two weeks, NanOlogy has launched trials evaluating its cancer-fighting paclitaxel nanoparticle suspension in patients with … Continued

More >

DFB Pharmaceuticals, CritiTech, and US Biotest Form NanOlogy™ for Clinical Development of Naked Nanoparticle Platform to Treat Cancer and Related Illnesses

September 12, 2017 05:30 AM Eastern Daylight Time FORT WORTH, Texas–(BUSINESS WIRE)–DFB Pharmaceuticals, a private investment and development group, in … Continued

More >